Melatonin suppresses TLR4‐mediated RSV infection in the central nervous cells by inhibiting NLRP3 inflammasome formation and autophagy

Respiratory syncytial virus (RSV) infects neuronal cells in the central nervous system (CNS), resulting in neurological symptoms. In the present study, we intended to explore the mechanism of RSV infection‐induced neuroinflammatory injury from the perspective of the immune response and sought to ide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular and molecular medicine 2024-05, Vol.28 (9), p.e18338-n/a
Hauptverfasser: Huang, Yixuan, Jiang, Chengcheng, Liu, Xiaojie, Tang, Wei, Gui, Hongya, Sun, Tao, Xu, Doudou, He, Maozhang, Han, Maozhen, Qiu, Huan, Chen, Mingwei, Huang, Shenghai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Respiratory syncytial virus (RSV) infects neuronal cells in the central nervous system (CNS), resulting in neurological symptoms. In the present study, we intended to explore the mechanism of RSV infection‐induced neuroinflammatory injury from the perspective of the immune response and sought to identify effective protective measures against the injury. The findings showed that toll‐like receptor 4 (TLR4) was activated after RSV infection in human neuronal SY5Y cells. Furthermore, TLR4 activation induced autophagy and apoptosis in neuronal cells, promoted the formation of the NOD‐like receptor family pyrin domain containing 3 (NLRP3) inflammasome, and increased the secretion of downstream inflammatory cytokines such as interleukin‐1β (IL‐1β), interleukin‐18 (IL‐18) and tumour necrosis factor‐α (TNF‐α). Interestingly, blockade of TLR4 or treatment with exogenous melatonin significantly suppressed TLR4 activation as well as TLR4‐mediated apoptosis, autophagy and immune responses. Therefore, we infer that melatonin may act on the TLR4 to ameliorate RSV‐induced neuronal injury, which provides a new therapeutic target for RSV infection.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.18338